Novo Nordisk ( NVO 5.29%) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli Lilly ...
Tirzepatide is just as effective in reducing cardiovascular risk driven by central adiposity as that driven by general ...
Novo Nordisk only prices in management's latest year guidance and underestimates the full market potential. See why I rate ...
Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The ...
Novo Nordisk's (NVO) weight loss therapy Wegovy/Ozempic come out of shortage, but the FDA won't crack down on compounders ...
Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...
Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...
Novo Nordisk (NVO) announced that the U.S. Food and Drug Administration has determined the shortage of Wegovy and Ozempic is resolved. “The ...
Shares tumbled 21% to $52.22. Over the last year, the stock has surged more than 450%.
The “Check Before You Inject” ad goes on to note that some vials of compounded semaglutide “have been found to contain ...
Demand GLP-1 Medications as Prescription Drug Market GrowsSchaumburg, Illinois, Feb 21, 2025 - (ACN Newswire) - Giftify, Inc.